Study on Rituximab and Zanubrutinib for Patients with Slow-Growing B-cell Lymphomas

Inclusion Criteria

• Patients with untreated marginal zone lymphoma (MZL) or follicular lymphoma (FL).
• Must have a confirmed diagnosis of MZL or FL, with available tissue samples for confirmation.
• MZL patients must require systemic treatment and can include nodal, splenic, or extra-nodal types.
• FL patients must have a pathological grade of 1, 2, or 3a.
• Disease must require systemic therapy, not just local radiation.
• Must have measurable disease, meaning a tumor or lymph node that is at least 1.5 cm in size.
• Cancer cells must have the CD20 marker.
• Must have symptoms or conditions that indicate the need for treatment.
• Must be 18 years or older.
• Must have a performance status score of 0 to 2, indicating good overall health.
• Must be able to swallow pills.
• Must be willing to follow the study requirements.
• Women must not be able to become pregnant or must have a negative pregnancy test.
• Participants of childbearing potential must agree to use effective birth control during and after treatment.
• Must have adequate organ function.

Exclusion Criteria

• Previous treatment for lymphoma, except for certain steroid use.
• Previous use of a BTK inhibitor.
• Known severe allergy to rituximab.
• History of other cancers unless disease-free for at least 2 years, with some exceptions.
• Evidence of aggressive lymphoma types.
• Lymphoma involving the central nervous system.
• Known bleeding disorders.
• Use of certain blood thinners.
• Need for certain medications that affect drug metabolism.
• Active infections or recent major infections.
• HIV infection.
• Active hepatitis B or C infections.
• Recent vaccination with a live vaccine.
• History of uncontrolled seizures.
• Significant heart disease or recent heart events.
• Uncontrolled high blood pressure.
• Recent stroke or brain bleeding.
• Recent major surgery.
• Any serious illness or condition that could affect safety or study results.